San Diego, CA, United States
Adamis Pharmaceuticals Corporation recalls
1 recall recorded since 2018, most recently on 21 March 2022. None are listed as ongoing. Status and classification are as published by the FDA.
Recalls1
Ongoing (FDA)0
Terminated or completed1
Class I (FDA)1
Terminated Class I Drugs
- Recall started
- 21 March 2022
- Terminated
- 8 February 2023
- Reason
- Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.
- Distribution
- Nationwide in the U.S.A.
- Initiated
- Voluntary: Firm initiated
- Recall numbers
- D-0764-2022, D-0763-2022
- SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Loui
- SYMJEPI (epinephrine injection, USP) 0.3 mg, (0.3 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Louis
A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.